| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $22,076,283 | 37 | 100 |
| Jacques Rachelle Suzanne | director | 0 | $0 | 1 | $53,931 | $-53,931 |
| Meek David D. | director | 0 | $0 | 1 | $53,931 | $-53,931 |
| POST LEONARD E | director | 0 | $0 | 1 | $53,931 | $-53,931 |
| Springhorn Jeremy P. | director | 0 | $0 | 1 | $53,931 | $-53,931 |
| Potts Jeannette | Chief Legal Officer | 0 | $0 | 3 | $261,172 | $-261,172 |
| KLEMT CHRISTIAN | Chief Financial Officer | 0 | $0 | 3 | $381,751 | $-381,751 |
| O'Keefe Kylie | Chief Customer & Strat Officer | 0 | $0 | 1 | $431,228 | $-431,228 |
| Balachandran Madhavan | director | 0 | $0 | 3 | $858,915 | $-858,915 |
| Gut Robert | director | 0 | $0 | 4 | $1.76M | $-1.76M |
| Abi-Saab Walid | Chief Medical Officer | 0 | $0 | 5 | $2.61M | $-2.61M |
| Kaye Jack | director | 0 | $0 | 6 | $2.69M | $-2.69M |
| Kapusta Matthew C | CEO, Managing Director | 0 | $0 | 8 | $12.86M | $-12.86M |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase …
Over the last 12 months, insiders at uniQure N.V. have bought $0 and sold $22.08M worth of uniQure N.V. stock.
On average, over the past 5 years, insiders at uniQure N.V. have bought $0 and sold $8.12M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-07-02 | Sale | Kapusta Matthew C | CEO, Managing Director | 21,082 0.0364% | $45.16 | $952,051 | -0.83% | |
| 2026-06-30 | Sale | Abi-Saab Walid | Chief Medical Officer | 30,000 0.0484% | $46.42 | $1.39M | -9.54% | |
| 2026-06-30 | Sale | Kaye Jack | director | 21,167 0.0341% | $46.44 | $983,030 | -9.54% | |
| 2026-06-26 | Sale | Abi-Saab Walid | Chief Medical Officer | 1,434 0.0022% | $46.86 | $67,197 | -11.60% | |
| 2026-06-25 | Sale | Kapusta Matthew C | CEO, Managing Director | 28,716 0.0464% | $50.02 | $1.44M | -14.07% | |
| 2026-06-24 | Sale | Kapusta Matthew C | CEO, Managing Director | 6,696 0.0108% | $50.00 | $334,800 | -13.33% | |
| 2026-06-18 | Sale | Kapusta Matthew C | CEO, Managing Director | 41,671 0.0714% | $50.00 | $2.08M | -7.91% | |
| 2026-06-17 | Sale | Kapusta Matthew C | CEO, Managing Director | 164,429 0.2399% | $44.32 | $7.29M | -11.35% | |
| 2026-06-17 | Sale | Balachandran Madhavan | director | 11,685 0.0173% | $45.06 | $526,485 | -11.35% | |
| 2026-06-17 | Sale | Kaye Jack | director | 5,295 0.0074% | $42.57 | $225,408 | -11.35% | |
| 2026-06-15 | Sale | Potts Jeannette | Chief Legal Officer | 5,237 0.0082% | $27.67 | $144,908 | +53.19% | |
| 2026-06-15 | Sale | Balachandran Madhavan | director | 10,000 0.0158% | $27.85 | $278,500 | +53.19% | |
| 2026-06-11 | Sale | O'Keefe Kylie | Chief Customer & Strat Officer | 15,936 0.0255% | $27.06 | $431,228 | +58.69% | |
| 2026-06-11 | Sale | Balachandran Madhavan | director | 1,993 0.0032% | $27.06 | $53,931 | +58.69% | |
| 2026-06-11 | Sale | Springhorn Jeremy P. | director | 1,993 0.0032% | $27.06 | $53,931 | +58.69% | |
| 2026-06-11 | Sale | Meek David D. | director | 1,993 0.0032% | $27.06 | $53,931 | +58.69% | |
| 2026-06-11 | Sale | POST LEONARD E | director | 1,993 0.0032% | $27.06 | $53,931 | +58.69% | |
| 2026-06-11 | Sale | Jacques Rachelle Suzanne | director | 1,993 0.0032% | $27.06 | $53,931 | +58.69% | |
| 2026-06-11 | Sale | Gut Robert | director | 2,726 0.0044% | $27.06 | $73,766 | +58.69% | |
| 2026-06-11 | Sale | Kaye Jack | director | 1,993 0.0032% | $27.06 | $53,931 | +58.69% |
| Increased Positions | 143 | +52.38% | 24M | +43.23% |
| Decreased Positions | 127 | -46.52% | 17M | -31.45% |
| New Positions | 70 | New | 10M | New |
| Sold Out Positions | 65 | Sold Out | 8M | Sold Out |
| Total Postitions | 289 | +5.86% | 62M | +11.78% |
| Fmr Llc | $141,733.00 | 9.77% | 6.06M | +5M | +411.63% | 2025-09-30 |
| Avoro Capital Advisors Llc | $103,956.00 | 7.17% | 4.44M | +819,444 | +22.61% | 2025-09-30 |
| Rtw Investments, Lp | $103,500.00 | 7.14% | 4.42M | -733,263 | -14.21% | 2025-09-30 |
| Ecor1 Capital, Llc | $93,302.00 | 6.43% | 3.99M | 0 | 0% | 2025-09-30 |
| Aberdeen Group Plc | $68,761.00 | 4.74% | 2.94M | +189,029 | +6.87% | 2025-09-30 |
| Franklin Resources Inc | $46,513.00 | 3.21% | 1.99M | +383,066 | +23.86% | 2025-09-30 |
| Blackrock, Inc. | $33,824.00 | 2.33% | 1.45M | +112,436 | +8.43% | 2025-09-30 |
| State Street Corp | $33,775.00 | 2.33% | 1.44M | +301,200 | +26.36% | 2025-09-30 |
| Fred Alger Management, Llc | $30,182.00 | 2.08% | 1.29M | +1M | New | 2025-09-30 |
| Jpmorgan Chase & Co | $26,883.00 | 1.85% | 1.15M | -658,334 | -36.42% | 2025-09-30 |